Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McNeil compliance with NAD

This article was originally published in The Tan Sheet

Executive Summary

Ad watchdog "considered it incredibly unfortunate" that a St. Joseph aspirin TV commercial "continued to air without modification for months after" NAD deemed the ad misleading, according to recent Case Reports. In February, CBBB division concluded McNeil should modify ad claims for St. Joseph to avoid inaccurately communicating 81 mg is the appropriate, recommended dosage for aspirin therapy (1"The Tan Sheet" March 25, 2002, p. 6). In response to NAD compliance proceeding, McNeil said original ad aired through May while revisions were planned and instituted. The case, brought by Bayer, has since moved to federal court (2"The Tan Sheet" April 29, 2002, p. 14)...

You may also be interested in...



Bayer, McNeil St. Joseph Aspirin Ad Dispute Moves To Federal Court

A recent British Medical Journal study does not support McNeil Consumer & Specialty Pharmaceuticals' advertising claims that 81 mg aspirin "is just as effective as 325 mg in reducing the risk of recurrent heart attacks," Bayer says in a lawsuit filed in New York federal court April 25

McNeil St. Joseph “Aspirin Therapy” Claim Needs Refining, NAD Says

McNeil Consumer & Specialty Pharmaceuticals should more narrowly target future advertising claims for St. Joseph Adult Low-Strength Aspirin "to avoid the risk of inaccurately communicating that 81 mg is the appropriate and recommended dosage for all types of 'aspirin therapy,'" the National Advertising Division says

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

Topics

UsernamePublicRestriction

Register

PS094790

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel